Beam Therapeutics (BEAM) Non Operating Income (2020 - 2026)

Beam Therapeutics (BEAM) has 7 years of Non Operating Income data on file, last reported at $12.9 million in Q1 2026.

• Non Operating Income for Q1 2026 came in at $12.9 million, up 17.72% year-over-year; the trailing twelve-month figure through Mar 2026 was $306.6 million (up 591.15% YoY), and the FY2025 annual result was $303.7 million, up 681.43% from the prior year.
• Non Operating Income eased to $12.9 million in Q1 2026 per BEAM's latest filing, from $261.7 million in the prior quarter.
• Over five years, Non Operating Income peaked at $261.7 million in Q4 2025 and troughed at $2.5 million in Q1 2023.
• A 5-year average of $28.2 million and a median of $11.3 million in 2023 frame the typical range for Non Operating Income.
• The sharpest annual moves came in 2022 and 2023: Non Operating Income soared 4322.08% in 2022, then slumped 78.11% in 2023.
• A 5-year view of Non Operating Income shows it stood at $51.6 million in 2022, then tumbled by 78.11% to $11.3 million in 2023, then decreased by 14.35% to $9.7 million in 2024, then soared by 2603.11% to $261.7 million in 2025, then plunged by 95.07% to $12.9 million in 2026.
• Business Quant data shows BEAM's Non Operating Income at $12.9 million in Q1 2026, $261.7 million in Q4 2025, and $14.1 million in Q3 2025.